Celcuity Inc. (CELC): Price and Financial Metrics
GET POWR RATINGS... FREE!
CELC Stock Price Chart Interactive Chart >
CELC Price/Volume Stats
| Current price | $21.29 | 52-week high | $33.01 |
| Prev. close | $20.50 | 52-week low | $5.00 |
| Day low | $20.99 | Volume | 66,500 |
| Day high | $22.37 | Avg. volume | 227,820 |
| 50-day MA | $25.16 | Dividend yield | N/A |
| 200-day MA | $17.01 | Market Cap | 269.25M |
Celcuity Inc. (CELC) Company Bio
Celcuity LLC, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. It develops CELx tests to diagnose breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is based in Minneapolis, Minnesota.
Latest CELC News From Around the Web
Below are the latest news stories about Celcuity Inc that investors may wish to consider to help them evaluate CELC as an investment opportunity.
Analysts Say Celcuity Can Change Targeted Therapy GameRising incidences of cancer is leading to an increase in the scope of work for research and diagnostics companies. Notably, research firm Markets and Markets projects the global cancer diagnostics market to hit $26.6 billion by 2026, witnessing a CAGR of 11.5% between 2021 and 2026. Celcuity (CELC), a leading player in this field, is currently focused on developing its next-generation cancer diagnostic discovery platform — CELsignia. The platform evaluates tumor cells for aberrant signaling in entire key pathways to ascertain the best candidates for targeted therapies. |
Celcuity: Nipping The Oncogenic Budselvanegra/iStock via Getty Images Celcuity, Inc. (CELC) is a clinical-stage biotechnology company founded in 2012, to better diagnose the cellular abnormalities driving cancer, so that patients can receive the drugs best suited to alleviate their disease burden. Molecular tests cannot diagnose the cancer driver in 80% of cancer patients, which... |
Celcuity to Participate in the William Blair Biotech Focus ConferenceMINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its |
Celcuity Inc.: Celcuity to Participate in the William Blair Biotech Focus ConferenceMINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating p |
Where Do Hedge Funds Stand On Celcuity Inc. (CELC)?No summary available. |
CELC Price Returns
| 1-mo | -12.49% |
| 3-mo | -23.03% |
| 6-mo | 45.82% |
| 1-year | 305.52% |
| 3-year | -11.77% |
| 5-year | N/A |
| YTD | 132.42% |
| 2020 | -13.91% |
| 2019 | -55.65% |
| 2018 | 26.60% |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...